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Summary 23 
We aimed to investigate the association between possible aetiological factors and the risk of 24 
developing vulval lichen sclerosus (VLS).  A population based case control questionnaire study was 25 
performed comparing women with a diagnosis of VLS (n=92) with those attending a general 26 
gynaecology clinic with no known anogenital dermatosis (n=66).  After adjustment for 27 
confounders, factors associated with VLS included a family history of diabetes mellitus (OR=7.0, 28 
p=0.012) and , previous pelvic surgery (OR=4.75, p=0.007). and current cigarette smoking 29 
(OR=5.54, p=0.044).  The use of barrier and progesterone only methods of contraception (OR=0.19, 30 
p=0.045), hormone replacement therapy (OR=0.209, p=0.025) or hayfever (OR=0.18, p=0.008) 31 
appeared to be associated with a reduced risk of VLS.  In conclusion, we were unable to confirm 32 
many proposed aetiological theories associated with the development of VLS, in particular those 33 
associated with autoimmunity. 34 
35 
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Introduction 36 
Vulval lichen sclerosus (VLS) is a chronic inflammatory dermatosis affecting skin in the anogenital 37 
region of women.  It is a progressive lifetime condition which runs a relapsing and remitting course 38 
of distressing symptoms including vulval itch, discomfort and pain.  For women affected by VLS 39 
there can be associated functional difficulties related to architectural changes of the vulva in 40 
addition to the increase in lifetime risk of developing vulval squamous cell carcinoma (Wallace, 41 
1971, Carli et al., 1995, Walkden et al., 1997, Van De Nieuwenhof et al., 2010).  The incidence of 42 
VLS is difficult to ascertain since mild symptoms may go undiagnosed and in addition some 43 
women may not volunteer problems in the face of potential embarrassment.  However previous 44 
studies have shown it accounts for at least 25% of the women seen in dedicated vulval clinics 45 
(Kirwan and Herod, 2002), and accounts for between one in 300 to one in 1000 of all patients 46 
referred to dermatology departments (Wallace, 1971).  47 
 48 
The aetiology of VLS remains elusive, but is most probably multifactorial.  A lack of aetiology 49 
affects the management of women with VLS in terms of available treatments and also counselling 50 
about the disease.  Evidence for proposed aetiological stimuli is conflicting, however possibilities 51 
include an autoimmune process (Meyrick Thomas et al., 1988, Powell et al., 2000, Cooper et al., 52 
2008), genetic susceptibility (Friedrich and MacLaren, 1984, Meyrick Thomas and Kennedy, 1986, 53 
Powell et al., 2000, Sherman et al., 2010),  low endogenous sex hormone levels and age (Friedrich 54 
and MacLaren, 1984, Marren et al., 1995, Hagedorn et al., 2002, Powell and Wojnarowska, 2002, 55 
Gunthert et al., 2008), chronic genital infection (Schempp et al., 1993, Dillon et al., 1995, Farrell et 56 
al., 1999b), genital trauma and the Kobner phenomenon (Pass, 1984, Yates et al., 1985, Todd et al., 57 
1994, Scurry, 1999, Farrell et al., 2006).  In addition, aetiological studies of VLS have been 58 
hampered in the past by confusion surrounding disease definition.  However, the consensus 59 
Page 3 of 23
URL: http:/mc.manuscriptcentral.com/cjog  Email: a.maclean@medsch.ucl.ac.uk





























































For Peer Review Only
4 
statements from the ISSVD (Lynch et al., 2007), should increase the applicability of future VLS 60 
research.  61 
 62 
In terms of modifiable aetiological exposure, little investigation has been undertaken, and is most 63 
often based solely upon observations of women with VLS with no comparison to rates of exposure 64 
among unaffected women. Sideri et al investigated modifiable risk factors for VLS with 65 
comparisons made with women admitted to hospital for other reasons (Sideri et al., 1989).  The 66 
main differences between groups were women with VLS were that they  had a lower dietary 67 
caritinoid intake of caritinoids and were parous.   68 
 69 
Overall, previous work has been limited by the aetiological factors examined and also through the 70 
lack of comparison of exposure in appropriate control groups and incomplete exploration of general 71 
aetiological factors.  Therefore, we aimed to use data from a retrospective case-control study 72 
comparing women with VLS and without an anogenital dermatosis to investigate the association 73 
between possible aetiological factors and the attached risk of being affected by VLS.  74 
 75 
76 
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Methods 77 
Patient selection and recruitment 78 
We conducted a retrospective case-control study nested with in a population based cohort. We 79 
compared women with a diagnosis of VLS with women who did not have an anogenital dermatosis.  80 
All women were recruited from the Grampian region of Scotland.  Cases of VLS were identified 81 
from the Grampian Gynaecology-Skin Clinic database, where secondary care of women with vulval 82 
disorders, including VLS, is centralised and staffed by Dermatology, Gynaecology and Sexual 83 
Health consultants.  Approximately 35% of women attending this clinic have a diagnosis of VLS.  84 
Women were included in the VLS group if it was biopsy confirmed or found to be clinically typical 85 
by one of the consultants at the dedicated clinic.  Women with VLS were recruited either during 86 
routine clinic attendance or by postal invitation.  Participants in the control group were recruited 87 
during attendance at a routine general gynaecology clinic, after pre-checking referrals to ensure that 88 
they had no known anogenital disorder.  Women giving informed consent were given the study 89 
questionnaire to complete.  Ethical approval was obtained from the Joint Grampian Research Ethics 90 
Committee (Ref No 03/0243). 91 
 92 
The study questionnaire was designed based on a literature review concerning possible aetiological 93 
factors responsible for the development of both systemic and anogenital lichen sclerosus in men and 94 
women.   The data collected included patient demographics, personal medical history with 95 
particular inclusion of obstetric, gynaecological and autoimmune related disorders, and familial 96 
medical history.  The draft questionnaire was piloted at the local vulval clinic at Aberdeen Royal 97 
Infirmary for ease of understanding.  98 
 99 
Statistical Analysis   100 
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Women were identified by a study number only, and standard security measures were taken.  Data 101 
was scanned directly into a Statistical Package for the Social Sciences Database, SPSS 15.0 (SPSS 102 
Inc., Chicago, IL) on a secure computer in preparation for analysis.   103 
 104 
Continuous variables are expressed as median and interquartile range.  Mann-Whitney U tests were 105 
used to determine differences between the two groups.  Odds ratios (OR) and 95% confidence 106 
intervals (CI) were calculated for each potential aetiological factor using binary logistic regression 107 
analysis and statistical significance was assumed at p<0.05.  Adjusted odds ratios are indicated in 108 
the text and were calculated for potential confounding factors including age, parity and menopausal 109 
status.  110 
 111 
112 
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Results 113 
A total of 158 women took part in this study; 92 women with VLS and 66 women with no vulval 114 
dermatoses acted as controls.  The median age of women in the VLS group was 65.0 (IQR 58.5, 115 
71.5) years which was significantly older than their counterparts in the control group, median age 116 
46.0 (IQR 37.5, 53.0) years.  Age was significantly associated with the presence of VLS (OR 1.13, 117 
95% CI (1.09, 1.17), p<0.001). 118 
 119 
Gynaecological History  120 
Gynaecological factors were examined in two groups, firstly those associated with menarche and 121 
contraception, and secondly those associated with general gynaecology and the menopause.  Data 122 
are shown in Table I. 123 
 124 
Menarche and contraception 125 
Using univariate analysis, age at menarche was associated with VLS, however, this was lost when 126 
adjusted for current age. In terms of contraception, barrier methods have a negative association with 127 
VLS which remained significant when corrected for current age, with a greater number of women in 128 
the non-LS groups having used barrier contraceptives.  The use of progesterone only preparations 129 
was also negatively associated with VLS, but became less significant when corrected for age. The 130 
use of combined oral contraception was negatively associated with VLS, however this association 131 
was lost when corrected for current age.  132 
 133 
General gynaecology and the menopause  134 
In this cohort, age at menopause was not associated with VLS. Menopausal status was associated 135 
with VLS, but this association was lost when corrected for current age.  When the effect of HRT 136 
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was examined and corrected for menopausal status and current age, women who have ever used 137 
HRT are less likely to be affected by VLS. 138 
 139 
No difference in risk of VLS was found in those who had previous pelvic and vulval infections, 140 
chronic vaginal discharge, cervical treatment or had exposure of the pelvis to radiotherapy.  There 141 
was an increased risk of VLS in the group who had previously had pelvic surgery (hysterectomy, 142 
pelvic floor repair, modified Fentons procedure), however the study design did not allow for 143 
analysis of reasons for surgery, and may reflect architectural changes as a result of damage by VLS 144 
rather than a stimulus for development of the condition in the first place.  145 
 146 
Obstetric History 147 
Associations between obstetric history and development of VLS are shown in Table II.  Parity did 148 
not alter odds of being affected by VLS.  However, delivery by forceps was positively associated 149 
with VLS, but this association was lost when corrected for parity and age. Interestingly, despite 150 
theories regarding a link between the genital trauma and VLS, perineal suturing and problems with 151 
perineal healing post delivery were not associated with VLS. 152 
 153 
Personal medical history  154 
The association between co-existing medical conditions and the development of VLS is illustrated 155 
in Table III, with multivariate analysis adjusting for differences in age at time of questionnaire.  156 
Both Type I and Type II diabetes mellitus are associated with VLS.  A personal history of hayfever 157 
is negatively associated with the odds of developing VLS and remains significant even when 158 
corrected for current age. Compared with those who have never smoked, current cigarette smoking 159 
decreased the odds of developing VLS, however, this did not remain significant when corrected for 160 
age.Additionally, smoking history is also associated with the odds of having VLS; compared to 161 
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those who have never smoked, current smoking is positively associated with a women being 162 
affected by VLS, even when corrected for age.  In particular it is of interest to note that when using 163 
a control group, the presence of a co-existing autoimmune disease does not alter the odds of being 164 
affected by VLS. 165 
 166 
Family medical history  167 
In the VLS group, 8 (8.7%) women had a relative who was also affected by VLS, whereas no 168 
women in the healthy group had a relative with VLS.  The number of relatives with diabetes is also 169 
higher in the VLS group and remains significant even when corrected for age, however the study 170 
design did not allow stratification for type of diabetes and type of relationship to relative with the 171 
condition.  No other familial medical disorders were associated with developing VLS with data 172 
shown in Table IV. 173 
 174 
175 
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Discussion 176 
In this population based case-control study we have examined aetiological factors contributing to 177 
the development of VLS in women.  We have shown a limited number of factors are associated 178 
with an increase in the odds of having VLS compared with healthy controls.  These include those 179 
with a history of diabetes mellitus or, pelvic surgery and current cigarette smoking,, with use of 180 
barrier contraception, exposure to progesterone only methods of contraception, HRT use and a 181 
medical history of hayfever being associated with a lower risk of being affected by VLS.   182 
 183 
Our data is in agreement with previous observational studies where the incidence of VLS among 184 
women increases with age (Marren et al., 1995, Hagedorn et al., 2002).  However, although 185 
menopausal status and age are linked, when we adjusted for age, menopausal status was not 186 
associated with VLS, suggesting that older age rather than menopausal status is linked with the 187 
development of VLS.   188 
 189 
The most commonly studied aetiological factor for VLS is autoimmune disease.  Previous 190 
observational studies have found women with VLS commonly have at least one co-existing 191 
autoimmune disease, in particular thyroid disease, vitiligo and alopecia (Meyrick Thomas et al., 192 
1988), however no healthy comparison group was studied.  Histologically, VLS specimens show 193 
immunological changes at all levels of the skin, showing typically a lichenoid pattern with a 194 
predominantly lymphocytic inflammatory infiltrate in the upper dermis with accompanying 195 
epidermal basal layer damage with local cytokine changes similar to those seen in lichen planus and 196 
chronic wounds (Farrell et al., 1999a, Farrell et al., 2006, Lynch et al., 2007).  Circulating IgG 197 
antibodies against extracellular matrix protein 1 (ECM1) have been found in women with VLS 198 
(Oyama et al., 2003).  Moreover, vulval carcinoma in association with VLS as opposed to VIN 199 
shows transcriptional over-activation of the immune response (Santegoets et al., 2009).  These 200 
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factors have lead to the suggestion that VLS is an autoimmune process and that new cases of VLS 201 
should be routinely screened for autoimmune diseases (Powell and Wojnarowska, 1999, Neill et al., 202 
2002, ACOG, 2008, Neill et al., 2010, RCOG, 2011).  Despite this, our results are in contrast to 203 
these studies with the data from our population based case-control study suggesting that the rates of 204 
co-existing autoimmune disease are similar among women with and without VLS.  This finding is 205 
also supported by local data from our department which was unable to detect increased rates of 206 
autoantibodies during routine screening of new cases of VLS at clinic (Higgins et al., 2002).  207 
Additionally, co-existing skin conditions including dermatitis and psoriasis does not affect risk.  208 
Again, this is in contrast to previous studies (Simpkin and Oakley, 2007), however, this perhaps 209 
reflects differences in study design where past observational studies have not considered data from 210 
healthy comparison groups. 211 
 212 
VLS has been linked to changes in sex steroid exposure due to its bimodal age distribution; VLS 213 
peaks in pre-menarchal girls, and post menopausal women (Marren et al., 1995, Powell and 214 
Wojnarowska, 1999, Hagedorn et al., 2002).  Despite this, our data found no significant association 215 
with age at menarche or menopause.  However, the data does suggest there may be a preventative 216 
benefit of systemic exogenous progesterone during the reproductive years, since women with VLS 217 
are less likely to have been exposed to progesterone only contraceptives, a risk which remains 218 
significant even when adjusted for current age.  Nevertheless, this protective benefit of systemic 219 
progesterone during reproductive life seems to be lost when combined with oestrogen, since there is 220 
no change in risk of VLS in users of combined oral contraception.  Furthermore, exposure to 221 
exogenous hormones in the form of HRT seems to have a protective effect against the development 222 
of VLS.  These hormonal associations suggest a possible role for sex steroid receptors in the 223 
aetiology of VLS.   224 
 225 
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Chronic genital infection has been proposed as a potential causative agent in the development of 226 
VLS (Schempp et al., 1993, Dillon et al., 1995, Farrell et al., 1999b).  This may be supported in part 227 
by our data where women unaffected by VLS are more likely to use barrier contraceptives, which 228 
can prevent exposure to infective agents.  However, this link is difficult to justify since within our 229 
study, other data did not support a role for chronic infection in VLS.  230 
 231 
We did show that women with VLS were more likely to have a first degree relative has affected by 232 
VLS, supporting proposals of a genetic predisposition (Friedrich and MacLaren, 1984, Meyrick 233 
Thomas and Kennedy, 1986, Powell et al., 2000).  However, it may simply be related to the nature 234 
of the study and issues connected with gynaecological conditions.  Firstly, individuals affected by 235 
any type of disease entity are more likely to have explored possible reasons for its developments, 236 
and therefore know if any other family members are affected.  Secondly, it is also likely to reflect 237 
the nature of vulval diseases and the associated embarrassment and lack of discussion of 238 
gynaecological problems within the general population.  239 
 240 
In relation to genital trauma and the development of VLS, our data did not demonstrate any 241 
association indicated by number and type of vaginal deliveries, perineal suturing and pelvic 242 
radiotherapy.  Pelvic surgery rates among women with LS are higher.  However, this is most likely 243 
to reflect firstly the higher number of hysterectomies and pelvic floor operations performed in the 244 
older age group of women, and secondly, it may be reflection of the need for surgery to correct 245 
architectural changes caused by VLS, rather than being an aetiological factor per se.  Unfortunately 246 
our study design did not allow further stratification.  247 
 248 
Although our data is interesting and provide a useful basis for focussed aetiological research and 249 
patient counselling, the recognised drawbacks of retrospective, questionnaire based case control 250 
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studies must be acknowledged.  These include our selection of controls, all of whom were identified 251 
from secondary care, and therefore may not truly reflect the overall population.  There will 252 
inevitably be an element of recall bias within our data since we have relied on patient self reporting, 253 
which is not as consistent as review of medical notes or ideally prospective studies.  Additionally, 254 
our response rates in each group may be considered as low, and with a relatively uncommon 255 
condition it may have ultimately been underpowered to address some of the factors, in particular 256 
autoimmunity.  However, this data set is the first of its kind and should be considered as providing 257 
pilot data on which to base future larger and sufficiently powered aetiological studies. 258 
 259 
In conclusion, despite an international consensus as to disease definition of VLS (Lynch et al., 260 
2007), aetiology remains uncertain with multiple factors proposed.  Using our data set, we have 261 
been unable to confirm many of the currently proposed factors.  We have however, shown that 262 
exposure to controlled doses of exogenous hormones in the form of contraceptive preparations and 263 
HRT, may have some protective effect.   In addition, the lack of association between co-existing 264 
auto-immune disease and VLS in our study does not support the current guideline suggesting 265 
autoantibody screening in women with VLS. 266 
267 
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Table I: Association between gynaecological history and probability of being affected by VLS.  Multivariate association 
performed to include current age* or  current age and menopausal status** 









Odds Ratio (95% CI) p-value Odds Ratio (95% CI) p value 
Age at menarche 
(years) 
 
13 (12, 14)  
[10, 16] 
13 (12, 14)  
[9, 16] 








1.06 (0.97,1.15) 0.193 0.95 (0.85,1.06) 0.349* 
       
 
N (%) with 
condition 






6(6.5%)  20 (30.3%) 0.16 (0.06,0.43) <0.001 0.20 (0.06,0.61) 0.005* 
Female 
sterilisation 
16(17.4%) 13 (19.7%) 0.86 (0.38,1.93) 0.712 0.64 (0.24,1.71) 0.370* 
Copper IUD 6(6.5%) 9 (13.6%) 0.44 (0.15,1.31) 0.140 0.50 (0.14,1.83) 0.293* 
COCP  33(35.9%) 45 (68.2%) 0.26 (0.13,0.51) <0.001 0.70 (0.30,1.62) 0.403* 
Progesterone 
contraception 
3(3.3%) 10 (15.2%) 0.19 (0.05,0.72) 0.014 0.19 (0.03,0.96) 0.045* 
Vaginal skin 
infections 
32 (34.8%) 21 (31.8%) 1.14 (0.58, 2.24) 0.697 1.33 (0.57, 12.49) 0.507* 
Pelvic infections 5 (5.4%) 3 (4.5%) 1.21 (0.28, 5.24) 0.802 2.08 (0.35, 12.49) 0.424* 
Vaginal 
discharge 
45 (48.9%) 44 (66.7%) 0.48 (0.25, 0.92) 0.028 0.75 (0.32, 1.75) 0.504* 
Treatment to 
cervix 
12 (13.0%) 20 (30.3%) 0.35 (0.16, 0.77) 0.009 0.43 (0.16, 1.19) 0.103* 
Pelvic surgery 30 (32.6%) 8 (12.1%) 3.51 (1.49, 8.28) 0.004 4.75 (1.53, 14.74) 0.007* 
Pelvic 
radiotherapy 
2 (2.2%) 0 (0%) / / / / 
Childhood 
vulval problems 
3 (3.3%) 1 (1.5%) 2.19 (0.22, 21.54) 0.501 2.52 (0.19, 33.89) 0.486* 
Post-
Menopausal 
72 (78.3%) 27 (40.9%) 5.20 (2.59,10.44) <0.001 1.22 (0.46,3.25) 0.692* 
HRT ever used 33 (35.9%) 24 (36.4%) 0.98 (0.51, 1.89) 0.949 0.209 (0.053, 0.818) 0.025** 
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Table II: Association between obstetric history and probability of being affected by VLS.  Multivariate association performed 
to include current age* or current age and parity**. 
 VLS No VLS Univariate Association Multivariate Association 
Factor 
N (%) with 
condition 
N (%) with 
condition 
Odds Ratio (95% CI) p-value Odds Ratio (95% CI) p-value  
Parity≥1 78 (84.8%) 49 (74.2%) 1.93 (0.88,4.27) 0.103 1.43 (0.51, 4.03) 0.500* 
SVD 67 (72.8%) 42 (63.6%) 1.53 (0.78,3.02) 0.219 0.43 (0.11,1.61) 0.208** 
Caesarean 
section 
6 (6.5%) 6 (9.1%) 0.70 (0.22,2.27) 0.549 4.77 (1.04,21.80) 0.044** 
Forceps 22 (23.9%) 6 (9.1%) 3.14 (1.20,8.26) 0.020 2.46 (0.71,8.56) 0.157** 
Ventouse 1 (1.1%) 3 (4.5%) 0.23 (0.02,2.27) 0.231 0.17 (0.10,2.76) 0.211** 
Tear requiring 
sutures 
52 (56.5%) 28 (42.4%) 1.76 (0.93,3.34) 0.082 0.86 (0.33,2.24) 0.759** 
Problems with 
perineal healing 
10 (10.9%) 10 (15.2%) 0.68 (0.27,1.75) 0.427 0.41 (0.12,1.34) 0.140** 
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Table I: Association between gynaecological history and probability of being affected by VLS.  Multivariate association 
performed to include current age* or  current age and menopausal status** 
 VLS No VLS  Univariate Association Multivariate Association 
Factor Median (IQR) [Range] 
Median (IQR) 
[Range] Odds Ratio (95% CI) p-value Odds Ratio (95% CI) p value 
Age at menarche 
(years) 
 
13 (12, 14)  
[10, 16] 
13 (12, 14)  







[31,55] 1.06 (0.97,1.15) 0.193 0.95 (0.85,1.06) 0.349* 
       
 
N (%) with 
condition 





contraception 6(6.5%)  20 (30.3%) 0.16 (0.06,0.43) <0.001 0.20 (0.06,0.61) 0.005* 
Female 
sterilisation 16(17.4%) 13 (19.7%) 0.86 (0.38,1.93) 0.712 0.64 (0.24,1.71) 0.370* 
Copper IUD 6(6.5%) 9 (13.6%) 0.44 (0.15,1.31) 0.140 0.50 (0.14,1.83) 0.293* 
COCP  33(35.9%) 45 (68.2%) 0.26 (0.13,0.51) <0.001 0.70 (0.30,1.62) 0.403* 
Progesterone 
contraception 3(3.3%) 10 (15.2%) 0.19 (0.05,0.72) 0.014 0.19 (0.03,0.96) 0.045* 
Vaginal skin 
infections 32 (34.8%) 21 (31.8%) 1.14 (0.58, 2.24) 0.697 1.33 (0.57, 12.49) 0.507* 
Pelvic infections 5 (5.4%) 3 (4.5%) 1.21 (0.28, 5.24) 0.802 2.08 (0.35, 12.49) 0.424* 
Vaginal 
discharge 45 (48.9%) 44 (66.7%) 0.48 (0.25, 0.92) 0.028 0.75 (0.32, 1.75) 0.504* 
Treatment to 
cervix 12 (13.0%) 20 (30.3%) 0.35 (0.16, 0.77) 0.009 0.43 (0.16, 1.19) 0.103* 
Pelvic surgery 30 (32.6%) 8 (12.1%) 3.51 (1.49, 8.28) 0.004 4.75 (1.53, 14.74) 0.007* 
Pelvic 
radiotherapy 2 (2.2%) 0 (0%) / / / / 
Childhood 
vulval problems 3 (3.3%) 1 (1.5%) 2.19 (0.22, 21.54) 0.501 2.52 (0.19, 33.89) 0.486* 
Post-
Menopausal 6472 (69.678.3%) 2247 (36.440.9%) 5.20 (2.59,10.44) <0.001 1.22 (0.46,3.25) 0.692* 
HRT ever used 33 (35.9%) 24 (36.4%) 0.98 (0.51, 1.89) 0.949 0.209 (0.053, 0.818) 0.025** 
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Table IV: Association between familial medical history and probability of being affected by VLS.  
Multivariate association performed to include current age 
 Vulval LS 
No vulval 
disease 







 (%) with 
condition 
Odds Ratio 
 (95% CI) 
p-value 
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